54
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Next-generation sequencing has generated a need for a broadly applicable method to remove unwanted high-abundance species prior to sequencing. We introduce DASH (Depletion of Abundant Sequences by Hybridization). Sequencing libraries are ‘DASHed’ with recombinant Cas9 protein complexed with a library of guide RNAs targeting unwanted species for cleavage, thus preventing them from consuming sequencing space. We demonstrate a more than 99 % reduction of mitochondrial rRNA in HeLa cells, and enrichment of pathogen sequences in patient samples. We also demonstrate an application of DASH in cancer. This simple method can be adapted for any sample type and increases sequencing yield without additional cost.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s13059-016-0904-5) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Detection and quantification of rare mutations with massively parallel sequencing.

          The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Although massively parallel sequencing instruments are in principle well suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. The keys to this approach, called the Safe-Sequencing System ("Safe-SeqS"), are (i) assignment of a unique identifier (UID) to each template molecule, (ii) amplification of each uniquely tagged template molecule to create UID families, and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are considered mutant ("supermutants") only if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

            Using in vitro gene amplification by the polymerase chain reaction (PCR) and mutation detection by the RNAase A mismatch cleavage method, we have examined c-K-ras genes in human pancreatic carcinomas. We used frozen tumor specimens and single 5 micron sections from formalin-fixed, paraffin-embedded tumor tissue surgically removed or obtained at autopsy. Twenty-one out of 22 carcinomas of the exocrine pancreas contained c-K-ras genes with mutations at codon 12. In seven cases tested, the mutation was present in both primary tumors and their corresponding metastases. No mutations were detected in normal tissue from the same cancer patients or in five gall bladder carcinomas. We conclude from these results that c-K-ras somatic mutational activation is a critical event in the oncogenesis of most, if not all, human cancers of the exocrine pancreas.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Anchored multiplex PCR for targeted next-generation sequencing.

              We describe a rapid target enrichment method for next-generation sequencing, termed anchored multiplex PCR (AMP), that is compatible with low nucleic acid input from formalin-fixed paraffin-embedded (FFPE) specimens. AMP is effective in detecting gene rearrangements (without prior knowledge of the fusion partners), single nucleotide variants, insertions, deletions and copy number changes. Validation of a gene rearrangement panel using 319 FFPE samples showed 100% sensitivity (95% confidence limit: 96.5-100%) and 100% specificity (95% confidence limit: 99.3-100%) compared with reference assays. On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma. AMP is a scalable and efficient next-generation sequencing target enrichment method for research and clinical applications.
                Bookmark

                Author and article information

                Contributors
                microfluidics@gmail.com
                Emily.Crawford@ucsf.edu
                Brian.Odonovan@ucsf.edu
                Michael.Wilson@ucsf.edu
                Eric.Chow@ucsf.edu
                Hanna.Retallack@ucsf.edu
                Joe@derisilab.ucsf.edu
                Journal
                Genome Biol
                Genome Biol
                Genome Biology
                BioMed Central (London )
                1474-7596
                1474-760X
                4 March 2016
                4 March 2016
                2016
                : 17
                : 41
                Affiliations
                [ ]Departments of Pathology and Laboratory Medicine, University of California San Francisco, San Francisco, CA USA
                [ ]Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA USA
                [ ]Howard Hughes Medical Institute, Chevy Chase, MD USA
                [ ]Integrative Program in Quantitative Biology, Bioinformatics, University of California San Francisco, San Francisco, CA USA
                [ ]Department of Neurology, University of California San Francisco, San Francisco, CA USA
                [ ]Center for Advanced Technology, Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA USA
                [ ]Medical Scientist Training Program, Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, CA USA
                Article
                904
                10.1186/s13059-016-0904-5
                4778327
                26944702
                0f2f850c-8aa5-4e99-ae31-ebae68cb20d8
                © Gu et al. 2016

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 20 November 2015
                : 18 February 2016
                Funding
                Funded by: FundRef http://dx.doi.org/http://dx.doi.org/10.13039/100007100, Sandler Foundation;
                Funded by: William K. Bowes, Jr. Foundation
                Funded by: FundRef http://dx.doi.org/http://dx.doi.org/10.13039/100000011, Howard Hughes Medical Institute;
                Funded by: FundRef http://dx.doi.org/10.13039/100006108, National Center for Advancing Translational Sciences;
                Award ID: KL2TR000143
                Award Recipient :
                Categories
                Method
                Custom metadata
                © The Author(s) 2016

                Genetics
                cas9,crispr,depletion,sequencing,rna-seq,infectious disease,cancer,diagnostics
                Genetics
                cas9, crispr, depletion, sequencing, rna-seq, infectious disease, cancer, diagnostics

                Comments

                Comment on this article